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A b s t r a c t  
The purpose of this investigation was to develop and evaluate different oral drug release delivery 
formulations namely, tablets and capsules, based on dextran, in order to determine how the quantity 
of dextran and the form-structure of the delivery systems influence drug release and release 
mechanisms. Theophylline was used as the model drug. All matrix tablets and one capsule 
formulation demonstrated sustained release profiles. The amount of dextran and its properties 
(particularly erosion) along with the form of the preparation were found to considerably affect the 
performance of the system, the release profiles and the mechanism of release. In all cases an 
increase in the quantity of dextran resulted in a decrease in the release rate indicating that acted as 
a kind of barrier and hindered the release of drug molecules from these formulations. Significant 
differences were also observed among the different preparations under examination, with the matrix 
tablets exhibiting the slowest drug release followed by the capsules.  By altering the 
dextran/theophylline ratio or the form of the preparation it is possible to obtain appropriate drug 
release. Consequently dextran appears to be a versatile material and a promising vehicle for the 
preparation of various oral sustained release drug delivery systems and relevant devices.  




Hydrogels have attracted considerable attention in recent years 
as sustained release preparations for drug delivery. Dextran 
hydrogels can be used for oral sustained release systems 
particularly in the colon area [1].  Up till now only a few articles [2-
4]  have been published on this subject but only in one of them 
pure dextran was used as a carrier [4].  Dextran it is derived from 
the bacterium Leuconostoc mesenteroides and can be described 
as a glucose homopolysaccharide with a linear polymer backbone 
structure in which linkages are almost entirely of the 1,6-a D-
type(95%) the remaining 5% being 1,3-a-D- linkages. The 1,6-a 
D-glycosid linkages of dextran are hydrolyzed by dextranases. 
The majority of dexran splitters in the human colon are anaerobic 
intestinal bacteria mainly of the genus Bacteroides, which produce 
dextranases. The bacteroides produce both endo- and 
exodextran-ases which cleave randomly along the dextran chain 
and at the terminal linkages,  respectively [5,6]. Thus we believe 
that our contribution will help researchers by providing them some 
essential information needed to design and manufacture 
sustained release oral preparations based on dextran. 
Today a number of design options are available to control or 
modulate the drug release from a drug delivery system. Most of 
the oral controlled release dosage forms are either  matrix or 
capsule systems [7-11].   These preparations may swell, gel and 
finally erode thus modulating the release process [8,12,13]. 
The aim of the present investigation was to develop and evaluate 
new oral sustained release delivery systems using dextran as a 
carrier and theophylline a rather water soluble drug (11.2 mg/mL) 
as a model drug. Secondly we aimed to examine the effect of the 
formulations on the rate of drug release. Two different 
formulations were prepared and evaluated, namely capsules and 
matrix tablets.      
Materials and Methods 
Materials  
The chemicals were obtained from commercial suppliers and 
used as received:  theophylline   (Sigma Chemical Co, USA), 
dextran from Leukonostoc  mesenteroides,  MW 5x106 ă 
40x106(Sigma Chemical Co, USA) and magnesium stearate 
(BDH Poole,  England). 
Matrix tablet and Capsule preparation  
The matrix tablets, (M), and capsules,(C), contained various 
quantities of theophylline with    dextran(see Table 1) and 1% w/w 
of magnesium stearate. They were mixed for 10 min in a Turbula 
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ăT2C mixer (Willy A.  Bachofen AG. Basel, Switzerland), then the 
tablets were compressed at a compressing pressure of 1400kg to 
a crushing strength of 8-10 kg, measured in the Erweka hardness 
tester (Erweka  Heusenstamm, Germany). The diameter of the flat 
face tablets was 9 mm and the height was 3 mm.  
Weight variation test was performed by taking 20 tablets or 
capsules using an analytical balance (Sartorius AG, Goettingen, 
Germany) according to the official method. Weight variation was 
found to fall within the USP limit (μ 0.5%). 
Friability of the tablets was determined by testing 10 tablets in a 
Roche friabilator (Erweka TA, Erweka Heusenstamm, Germany) 
for 5 minutes at 25 rpm performed in triplicate. 
Tablet friability was found in the region of 1 %. The mixing 
process described above was also followed for the powders filled 
into the capsules. The exact weight of powder was filled manually 
into each capsule of size 1 for 200mg/20mg and size 0 for 
200mg/35mg and 200mg/60mg  mixtures, (see Table 1). The 
filling was performed at maximum bulk density. Each capsule was 
individually weighed before filling. All formulations are shown in 
Table 1.  
 
In vitro drug release studies  
The dissolution study of theophylline tablets or capsules was 
carried out in a USP dissolution tester, paddle method for tablets 
(apparatus 2) and basket method (apparatus 1)  for capsules 
(Pharmatest,  Hainberg, Germany), in 900 ml with stirring at 100 
rpm, at 37 ± 0.5 0C. The dissolution media consisted of 0.1N HCI, 
pH ‘1.2, for 2h, and then phosphate buffer pH ‘ 6.8, for 6h. 
Samples were withdrawn in selected time interval filtered and 
analyzed at 275 nm, using a Perkin Elmer UV spectrophotometer 
(Norwalk, CT, USA).  An equivalent volume of temperature-
equilibrated fluid was replaced into the dissolution bath following 
the removal of each sample. The data represent the mean values 
of at least six separate experiments. Results are given as mean μ 
standard deviation.  
Dissolution efficiency values (D.E.), first suggested by Khan [14], 
is a parameter useful for the evaluation of in vitro dissolution. D.E. 















                          
( 1 ) 
where y is the percentage of dissolved product and D.E. the area 
under the dissolution curve between time points t1 and t2 
expressed as a percentage of the curve at maximum dissolution, 
y100 over the same time period.  When a relationship is to be 
shown between dissolution and another variable, it is considered 
realistic to use D.E. which takes into account the dissolution 
profile as a whole [14]. Βesides, where a quantitative comparison 
is required,  D.E. is a more suitable parameter and when limits are 
set on D.E. it can be used for quality control in place of the 
conventional dissolution level. 
Erosion studies   
Weighted tablets were placed in dissolution vessels, containing 
900 ml under stirring at 100 rpm, at 37 ± 0.5 0C.  The dissolution 
media consisted of 1N HCI (pH ‘ 1.2) for 2h and then phosphate 
buffer pH ‘ 6.8. To prevent floating, tablets were placed under a 
„tent‰ which was formed from a pre-weighted 4 cm x 4 cm metal 
mesh (no 10) square.  At selected time intervals an individual 
tablet was withdrawn using the mesh „ tent „.   The mesh and the 
tablet were blotted to remove excess water and then weighted on 
a Sartrorius analytical balance. The wetted tablets were dried in 
an oven at 65 0C for a 24 h period then, before weighing, cooled 
in a desicator and finally weighted. This was repeated until 
constant weight was achieved (final dry weight). Three different 
tablets were measured for each time point, and fresh tablets were 
used for each individual time point.  
The extent of erosion (E) was determined from 
 
E% = 100 ( Wi-Wf ) /  Wi                                       ( 2 ) 
 
Where Wi and Wf are the initial starting dry weight and final dry 
weight of the same dried and partially eroded tablet, respectively. 
Optical examination of matrix tablets 
The system and the method we used were similar to the 
technique described in a previous study [15,16]. The recorded 
images were collected and analyzed with a Leica image analysis 
system (Leica Q 5001 W). A video camera (JVC TK-C11381, 
Japan) was fitted with a zoom lens (Century Precision Optics AD-
5870, USA) and connected to a monitor. The light system 
consisted of a fluorescent tube fitted under the beaker. The 
beaker was covered to prevent external light. The tablet was held 
on a pin and placed in a dissolution beaker (of a dissolution 
apparatus Pharmatest, Hainburg, Germany) containing the 
appropriate medium.  It was mounted in a vertical or horizontal 
direction to allow the observation of swelling in the axial or radial 
direction. The beaker was removed, at predetermined time 
intervals from the dissolution apparatus and was transferred to the 
optical image set up. The tablet was photographed by means of a 
video camera to record the axial and radial changes of the 
swelled tablet and to estimate the gel thickness growth. The gel 
layer appears as a sharp, bright white ring around the tablet due 
to the scattering of light by the hydrated polymer. The glassy core 
and the medium appear black, as they do not permit scattering of 
the incoming light. The swelling values of axial, radial and gel 
layer were obtained by calibration of the obtained image. The 
dimensional scale was calibrated from the known tablet size and 
measurement of the image obtained at t=0. Results reported are 
averages for three different tablets. 
Statistical analysis  
Dissolution results were given as mean μ standard deviation 
(S.D.) and were analyzed using studentÊs t-test (P< 0.05). 
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Results and Discussion  
During the dissolution process liquid penetration into the mass of 
a matrix tablet or capsule is the first step followed by dissolution of 
the drug contained within and finally its diffusion.  
In vitro drug release 
In Figure 1, we illustrate the release profiles of theophylline from 
the different formulations. As seen from the results the extent of 
drug release varies among the formulations and was affected by 
the type of the formulation and the amount of dextran contained. 
Capsules displayed the highest release and release rate followed 
by the matrices as clearly demonstrated by the t50 and D.E. 
values and this was probably because the powder in the capsules 
was not compressed. Furthermore, in all cases an increase in 
dextran content resulted in a lower overall drug release and a 





Figure  1.   Dissolution profiles of capsules and tablets. Each point  
represents the mean value of the three samples and error bars 
show μ   S.D. 
 
From Figure 1a it is apparent that the capsule with the smallest 
amount of dextan (20mg) (C3) exhibited the highest release and 
the drug was completely released within 90-100 min, while the 
capsule containing  the intermediate amount (40mg) (C2) of 
dextran released the drug in 480 min. The preparation with the 
largest amount (60mg) (C1) of dextran released only 70% of the 
drug after 8h.  
Matrix tablets exhibited a slower release of the drug i.e. 80, 60 
and 42% was release with a dextran content of  20 (Μ3), 40 (Μ2) 
and 60 (Μ1) mg, respectively (Fig. 1b). These results showed 
that the polymer may act as a strong barrier, controlling drug 
release from the matrices.  This could be attributed to the high Tg 
value of dextran(>150 0C) [15] which could influence the transition 
of dextran from its glassy to a rubbery state. As a result the liquid 
penetration into the dry polymer mass is delayed and drug 
dissolution and release is decreased. 
Previous studies on dextran mixtures tablets [2]  containing 
soluble propranolol HCI (50 mg/ml in water) exhibited complete 
release of the drug, while in our  findings with pure dextran tablets 
containing the less soluble theophylline (11.2 mg/mL)  incomplete 
release was observed. Consequently it is possible that a decrease 
in dextran content might result in  complete drug release. 
 The erosion results are shown in Figure 2.  The capsules 
exhibited a very high erosion, almost twice that of the matrices 
(after 8 h).  More specifically 40 and 20 mg capsules displayed 
100 % erosion, while the formulation containing 60mg dextran 
displayed 80 % erosion, Figure 2a. In contrast tablets containing 
20, 40 and 60 mg dextran respectively, exhibited lower erosion 
i.e. 75, 60 and 45% respectively, Figure 2b. 
The higher erosion exhibited by capsules, compared to tablets, 
could be attributed to the fact that capsules are uncompacted 
preparations with a loose structure that facilitates  liquid 





Figure  2.   Percentage of erosion for capsules and tablets as a 
function of time. Each point represents the mean value of the 
three samples and error bars  show μ  S.D. 
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In general the formulations with lower concentrations of dextran 
demonstrated greater erosion and these results were consistent 
with the release data. 
 
Tablet dimensional and gel layer changes.  
On placing the tablet in liquid, a rapid and substantial increase in 
size was observed in both radially and axially directions.  Due to 
rapid liquid penetration, all tablets underwent fast hydration. They 
swelled/expanded and created a rather thick gelatinous polymer 
mass. Three features are clearly visible from the images: a) the 
evolution of the gel layer with time, b) the change in size of the dry 
core of the polymer as more of the polymer becomes hydrated, 
and c) an increase in the dimensions of the tablet with time. 
In Figure 3, typical images of dextran-theophylline tablets 
undergoing hydration- swelling and the changes in their 
morphology after 30, 90 and 420 min are shown. In images 
undergoing hydration after 30, 90 and 420 min. these 
photographs the recorded time intervals were chosen in order to 
expose some of the major changes that occur during the 
dissolution process.  
 




Figure 3.   Morphological changes of the tablets during 
dissolution. Typical  
 
The radial (RAD) and axial (AX) dimensional changes with time 
(normalized to the dry tablet) for all tablets were computed. The 
normalized tablet dimensions are defined as R(t)/R(0) for the 
radial direction and A(t)/A(0) for the axial direction, respectively, 
where R(0) and A(0) are the dimensions at time = 0; R(t) and A(t) 
are the dimensions at time = t. 
Visual observations reveal that there was considerable expansion 
in both directions  
and all tablets displayed anisotropic swelling behavior with 
preferential axial expansion in accordance with previous studies 
[16]. 
Moreover an increase in dextranÊs content resulted in an increase 
in tablet dimensions.  More specifically the 20 mg formulation 
exhibited a 1.60 fold axial expansion the 40 mg formulation a 1.70 
fold expansion and the 60 mg a 1.78 fold expansion, while radial 
expansion was smaller ranging from 1.20 to 1.25 folds, (not 
shown here).  It is noteworthy that after initial expansion, 
particularly after the 3rd hour, a gradual decrease in both 
dimensions was observed until the end of the experiment. The 
determination of the diameter(RAD) and thickness(AX) of the 
expanded tablet allowed us to calculate the corresponding total 
surface area using the formula,  Area = 2r « (r+h).  The results 
obtained were normalized to the surface of a dry tablet and are 
shown in Figure 4. These results match with erosion data, (Fig. 
2b) and support each other.  It is obvious that tablets containing 
larger amounts of dextran exhibited greater surface areas, due to 
their greater axial and radial expansion. 
 
                         
 
Figure  4.   Surface changes of the tablets during hydration. Each 
point represents the mean value of the three samples and error 
bars show μ S.D. 
 
Our visual examination showed that around the surface of the 
swelled tablets a highly viscous gel layer was created, Figure  3. 
The relative movement of the erosion and swelling fronts 
represents the gel layer thickness. The gel layer thickness and its 
 changes appear to play an important role and determine the drug 
release from swellable delivery systems [17,18]. Therefore it was 
important to investigate the development of a gel for the dextran 
tablets under examination. 
The next step we made was to determine the evolution of the gel 
layer and the changes of its thickness with time.  The distance 
from the gel/core interface to the outer surface of the gel was 
taken as a measurement of the thickness of the layer.  It was 
detected that the rate and the extent of gel growth was different 
for both the radial and the axial dimensions.  In earlier studies 
[17,18] it was suggested that, for better precision and evaluation, 
it is preferable to use the average radial and axial gel thickness.  It 
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was apparent with all tablets that the gel thickness increased 
rapidly in the beginning up to the 2th  hour; (Figure. 5).   
Afterwards the rate of growth and the thickness decreased 
followed by a plateau until the end of the experiment. This finding 
indicated that there was a synchronization of swelling and erosion 
fronts and stabilization of gel thickness. The gel thickness of the 
60 mg matrices was greater reaching a maximum 1.85mm, 
followed by the 40 and 20 matrices with 1.50 and 1.25 mm 
respectively. The above results may explain the smaller release 
and release rate from the 60 mg matrices compared to the 40 and 
20 mg matrices, since the greater thickness of the gel layer acts 
as a strong barrier that decreases the diffusion rate of drug 




                                       
 
Figure  5.  Gel thickness increase versus time. Each point 
represents the mean  
 value of the three samples and error bars show μ S.D.  
Capsule morphological changes  
Visual observations showed that 10-15 minutes after the capsule 
was immersed in our dissolution medium the capsule shell was 
dissolved and the remaining mass tent to form gel-like cylinder as 
the polymer hydrated and swelled. With time became an 
amorphous mass. Observations during the dissolution procedure 
showed that the polymer mass was reduced gradually in all 
cases. 
Drug release from this mass was controlled by the viscous gel 
layer formed around the capsule mass. The layer acted as a 
barrier to drug release by obstructing the movement of dissolved 
solutes out of the polymer mass [19]. 
As time elapsed the polymer mass decreased as a result of 
erosion and dissolution of the polymer, resulting in increased drug 
release (Figs 1a,2a).  In Figure 6, this procedure is clearly 
illustrated as well as the shrinking of the polymer mass for the 
capsules containing 60 mg of Dextran(as an example) from the 
beginning till the end of the experiment. Photos displayed in 
Figure 6 confirm these findings. In these photographs the 
recorded time intervals were chosen in order to demonstrate 
some of the major changes that occur during the dissolution 
process.  
Gradual erosion started a little after 30 min and by 480 min only 
80% of the mass had eroded. As is apparent the erosion can be 
compared to the progressive release of the drug, (Figs 1a and 
2a). Capsules with 20 or 40 mg of Dextran exhibited a more rapid 






Figure  6.  Morphological changes of the capsules during 
dissolution. Typical  
 images undergoing hydration after 0, 60, 120, 240, 420 480 min.  
Effects of erosion on drug release 
Figure 7 demonstrates the relationship between drug release and 
erosion for the 60 mg formulations. The results reveal that erosion 
plays a decisive role; it decreases the total surface area and 
subsequently shortens the distance that the dissolved drug has to 
travel from the interior of the formulation to the dissolution front 
and the surrounding medium. Thus with the decrease in surface 
area an increase in drug release was observed (Fig 8). 
Polymer erosion could be attributed to itsÊ dissolution as a result 
of chain disentanglement leading to shrinking of the gel layer and 
therefore increased drug release. 
As seen in the graphs, (Figure 7), the association between 
release and erosion is comparable for these formulations. Greater 
erosion corresponds with increased drug release.  From these 
results it appears that drug release could be attributed to both a 
swelling and a erosion/dissolution mechanism. The latter 
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dominates the last stages when erosion of the polymer mass 
becomes more intense. This fact was also confirmed by visual 
inspection during the dissolution studies. 
Figure 9 illustrates the relationship between the amounts of 
Dextran and the D.E. It is obvious that the matrix tablets exhibit a 
linear correlation in contrast to the capsules. 
 
 








Figure  9.   Relationship between the quantities of  Dextran and 
the D.E 
 
Table 1.    Formulation compositions 
 
Formulations Ingredients in  mg  





   
M1    Matrix 200 60 2.6 >480 20.0μ0.7 1.01
M2       >>  >> 40 2.4  370 34.0μ0.9 0.84
M3       >>  >> 20 2.2  220 48.0μ1.0 0.80
C1   Capsules  >> 60 2.6  340 39.0μ1.2 0.66
C2       >>  >> 40 2.4    25 80.0μ1.5 N.A.
C3       >>  >> 20 2.2    16 95.0μ1.5 N.A.
   
 
Mg. st. = magnesium stearate, D.E. = Dissolution efficiency, N.A. = we do not have sufficient data for the calculation of n values. 
 
Kinetics and mechanism of drug release 
In order to clarify, identify and explain the mechanism of drug 
release, the data were further analyzed, up to 60% drug release, 
using the familiar empirical equation proposed by Korsmeyer and 
Peppas [20,21]: 
 Mt /M∞ = k tn                                           (3) 
where Mt /M∞  is the fractional release of the drug released at time 
t, k is the kinetic constant and n is the diffusional exponent for 
drug released which depends on the release mechanism.  Values 
n = 0.45 indicate Fickian release, 0.45<n<1 indicate anomalous 
non-Fickian release kinetics (coupled diffusion/relaxation) and n = 
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1 for Case II transport (zero order release also known as purely 
relaxation-controlled drug  release)(19). 
The n values obtained (listed in Table 1), ranged from 0.67 to 
1.01.  The n values for  the matrices M1, M2 and M3 (1.01, 0.84 
and 0.80, respectively) indicate that  drug release mechanism was 
due mainly to a macromolecular relaxation and erosion 
mechanism exhibiting a near zero-order release. It is apparent 
from our findings that an increase in the n value is associated with 
an increase in the dextran contained in a preparation.  On other 
hand the C1 capsule preparation displayed a rather Fickian 
diffusion, n =0.66. For the preparations C2 and C3 we could not 
calculate the n values due to lack of data. 
Conclusions  
The influence of dextran and the form-structure of the examined 
formulations were investigated. All matrix tablets and one of the 
capsule formulations exhibited sustained release profiles. It was 
demonstrated that the amount of dextran and its erosion along 
with the structure of the formulation considerably affect the 
performance of the formulation as well as the release profiles and 
the mechanism of release. An increase in dextran quantity results 
in a decrease in the release rate indicating that dextran is a strong 
barrier that may obstruct the release of drug molecules from these 
formulations.  Our findings show that marked differences were 
observed between these preparations, and the matrix tablets 
exhibited the slowest release followed by the capsules.  By 
altering the dextran/theophylline ratio or the form structure it is 
possible to obtain appropriate drug release. 
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